Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Homeopathy for Asthma on December 17, 2018 at 10:27 am
According to the U.S. Centers for Disease Control and Prevention, more than 26 million children and adults in the United States have asthma. According to the 2012 National Health Interview Survey, an ... […]
- Scientists found molecular 'switch' for allergic asthma treatment on December 17, 2018 at 7:19 am
A team of Russian scientists identified the role of the interleukin-6 molecule in the development of allergic asthma. Now it can be a new target for the treatment of this disease. The results are publ... […]
- The Return Of OTC Asthma Inhaler Primatene Mist on December 17, 2018 at 1:27 am
(RTTNews.com) - After 7 years of absence, asthma inhaler Primatene Mist, developed by Amphastar Pharmaceuticals, is reentering the market with renewed features. The over-the-counter epinephrine inhala... […]
- Don't let holiday season stress worsen your allergies, asthma on December 16, 2018 at 7:36 am
(HealthDay)—Reducing stress could cut your risk of allergy and asthma symptoms during the holidays. "Studies show stress can cause a number of negative health effects, including causing more ... […]
- Teen’s asthma frames town’s struggle with dirty air on December 15, 2018 at 9:10 am
From her front porch, Collette Williams can see the lights of US Steel’s Clairton Coke Works, the largest coke plant in North America, between the houses across the street. She can also pick out the d... […]
- URI study uses mobile tech to help repair asthma patients' lungs on December 14, 2018 at 8:57 am
This post was contributed by a community member. A number of patients who suffer from asthma are bringing their condition under control, increasing their lung function and decreasing the frequency ... […]
- Study helping to repair asthma patients' lungs on December 14, 2018 at 7:05 am
A number of patients who suffer from asthma are bringing their condition under control, increasing their lung function and decreasing the frequency of asthma attacks—all without going to the ... […]
- New tool could improve asthma prediction in children on December 13, 2018 at 9:25 am
Dec. 13 (UPI) --A new tool has could supplant the old standard for predicting asthma in children, a study says. Some doctors say using the Asthma Predictive Index, or API, to forecast asthma in kids i... […]
- Cincinnati Children’s researchers create tool to predict asthma on December 13, 2018 at 8:25 am
Cincinnati Children's Hospital scientists have created a tool that appears to be the most accurate, noninvasive method yet developed to predict asthma in young children. Researchers hope the Pediatric ... […]
via Bing News